ANAB Valuation

AnaptysBio Inc

Add to Watchlist

Advanced Chart

21.030

+0.66(3.240%)1D

Overview
Forecast
Valuation
Earnings

ANAB Relative Valuation

ANAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANAB is overvalued; if below, it's undervalued.

Historical Valuation

AnaptysBio Inc (ANAB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.60 is considered Undervalued compared with the five-year average of -4.20. The fair price of AnaptysBio Inc (ANAB) is between 22.59 to 149.44 according to relative valuation methord. Compared to the current price of 21.03 USD , AnaptysBio Inc is Undervalued By 6.92%.

Relative Value

Fair Zone

22.59-149.44

Current Price：21.03

6.92%

Undervalued

-4.52

Trailing

Forward

-6.17

EV/EBITDA

AnaptysBio Inc. (ANAB) has a current EV/EBITDA of -6.17. The 5-year average EV/EBITDA is -2.38. The thresholds are as follows: Strongly Undervalued below -10.36, Undervalued between -10.36 and -6.37, Fairly Valued between 1.62 and -6.37, Overvalued between 1.62 and 5.61, and Strongly Overvalued above 5.61. The current Forward EV/EBITDA of -6.17 falls within the Historic Trend Line -Fairly Valued range.

-4.41

EV/EBIT

AnaptysBio Inc. (ANAB) has a current EV/EBIT of -4.41. The 5-year average EV/EBIT is 0.77. The thresholds are as follows: Strongly Undervalued below -38.69, Undervalued between -38.69 and -18.96, Fairly Valued between 20.50 and -18.96, Overvalued between 20.50 and 40.24, and Strongly Overvalued above 40.24. The current Forward EV/EBIT of -4.41 falls within the Historic Trend Line -Fairly Valued range.

6.60

AnaptysBio Inc. (ANAB) has a current PS of 6.60. The 5-year average PS is 29.36. The thresholds are as follows: Strongly Undervalued below -20.41, Undervalued between -20.41 and 4.48, Fairly Valued between 54.25 and 4.48, Overvalued between 54.25 and 79.14, and Strongly Overvalued above 79.14. The current Forward PS of 6.60 falls within the Historic Trend Line -Fairly Valued range.

-7.68

P/OCF

AnaptysBio Inc. (ANAB) has a current P/OCF of -7.68. The 5-year average P/OCF is 21.09. The thresholds are as follows: Strongly Undervalued below -133.18, Undervalued between -133.18 and -56.05, Fairly Valued between 98.23 and -56.05, Overvalued between 98.23 and 175.37, and Strongly Overvalued above 175.37. The current Forward P/OCF of -7.68 falls within the Historic Trend Line -Fairly Valued range.

-6.37

P/FCF

AnaptysBio Inc. (ANAB) has a current P/FCF of -6.37. The 5-year average P/FCF is -2.23. The thresholds are as follows: Strongly Undervalued below -41.52, Undervalued between -41.52 and -21.88, Fairly Valued between 17.42 and -21.88, Overvalued between 17.42 and 37.07, and Strongly Overvalued above 37.07. The current Forward P/FCF of -6.37 falls within the Historic Trend Line -Fairly Valued range.

AnaptysBio Inc (ANAB) has a current Price-to-Book (P/B) ratio of -13.15. Compared to its 3-year average P/B ratio of 16.34 , the current P/B ratio is approximately -180.48% higher. Relative to its 5-year average P/B ratio of 10.49, the current P/B ratio is about -225.33% higher. AnaptysBio Inc (ANAB) has a Forward Free Cash Flow (FCF) yield of approximately -22.46%. Compared to its 3-year average FCF yield of -16.61%, the current FCF yield is approximately 35.21% lower. Relative to its 5-year average FCF yield of -12.01% , the current FCF yield is about 87.01% lower.

-13.15

P/B

Median3y

16.34

Median5y

10.49

-22.46

FCF Yield

Median3y

-16.61

Median5y

-12.01

Competitors Valuation Multiple

The average P/S ratio for ANAB's competitors is 15.33, providing a benchmark for relative valuation. AnaptysBio Inc Corp (ANAB) exhibits a P/S ratio of 6.60, which is -56.94% above the industry average. Given its robust revenue growth of 102.93%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Tango Therapeutics Inc

Stoke Therapeutics Inc

Sionna Therapeutics Inc

Performance Decomposition

Market capitalization of ANAB decreased by 44.79% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 10.97M to 22.26M.

The secondary factor is the Margin Expansion, contributed -59.20%to the performance.

Overall, the performance of ANAB in the past 1 year is driven by Revenue Growth. Which is more sustainable.

102.93%

10.97M → 22.26M

Revenue Growth

-59.20%

-425.30 → -173.52

Margin Expansion

-88.52%

-41.04 → -4.71

P/E Change

-44.79%